Biotech & Genomic Medicine▲
Tenon, Nuvectis, REGENXBIO Lead Biotech Gainers on Filings and Deals
Several biotech stocks posted sharp gains Monday, led by Tenon Medical after an S-1 filing, Nuvectis Pharma on a licensing deal with Haisco, and REGENXBIO on a regulatory reversal for its Hunter syndrome gene therapy. Tenon filed to offer up to 1.81 million shares and 6.98 million warrants at $0.6021 per unit, with shares closing up 77.57% at $0.62. Nuvectis announced exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group, sending its stock up 19.61% to $16.53. REGENXBIO gained 16.28% to $9.07 after the FDA agreed that existing data for NAVSUNLI is sufficient for an accelerated approval resubmission, with a Type A meeting set for next month and BLA resubmission expected in the third quarter of 2026. Other notable movers included Azitra, up 33.95% after a shareholder letter outlined a 2026 roadmap for its cosmetic ingredient program ATR-COSF, and Apollomics and Faeth Therapeutics, both rising over 30% on no specific news.